Precision BioSciences, Inc.
302 East Pettigrew Street
Durham
North Carolina
27701
United States
Tel: 919-314-5512
Fax: 480-393-5553
Website: http://www.precisionbiosciences.com/
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
237 articles about Precision BioSciences, Inc.
-
Precision BioSciences to Present at Hep-DART 2023
11/30/2023
Precision BioSciences, Inc. today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.
-
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
11/28/2023
Precision BioSciences, Inc. today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee.
-
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
11/13/2023
Precision BioSciences, Inc. announced that the company will present late-breaking data at the American Association for the Study of Liver Diseases’ The Liver Meeting being held in Boston, MA.
-
Precision BioSciences to Present at Upcoming Sidoti Conference
11/10/2023
Precision BioSciences, Inc. announced that the Company will present at the Sidoti November Micro Cap Conference taking place November 15-16, 2023.
-
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
11/9/2023
Precision BioSciences, Inc. today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.
-
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
11/7/2023
Precision BioSciences, Inc. announced financial results for the third quarter ended September 30, 2023 and provided a business update.
-
Precision BioSciences to Report Third Quarter Results on November 7, 2023
11/1/2023
Precision BioSciences, Inc. today announced that it will publish financial results for the third quarter 2023 and provide a business update on November 7, 2023.
-
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
10/26/2023
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.
-
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
10/23/2023
Precision BioSciences, Inc. today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023.
-
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
10/12/2023
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.
-
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
9/27/2023
Precision BioSciences, Inc. today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.”
-
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
9/12/2023
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments.
-
Precision BioSciences to Attend and Present at Upcoming September 2023 Investor Conferences
9/6/2023
Precision BioSciences, Inc., a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, announced that members of management will participate in the following investor conferences in the month of September.
-
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
8/31/2023
Precision BioSciences, Inc., a gene editing company developing ARCUS®-based in vivo gene editing therapies, announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET.
-
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
8/15/2023
Precision BioSciences, Inc. (Nasdaq: DTIL) today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.
-
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
8/4/2023
Precision BioSciences, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a business update.
-
Precision BioSciences to Report Second Quarter Results on August 4, 2023
8/1/2023
Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, announced that it will publish financial results for the second quarter 2023 and provide a business update on August 4, 2023.
-
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
7/27/2023
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day.
-
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
6/22/2023
Precision BioSciences Announces Oral Presentation of Positive ARCUS ® Gene Editing Data at International Liver Congress 2023.
-
Precision BioSciences to Present at Upcoming June Investor Conferences
6/5/2023
Precision BioSciences, Inc. today announced that members of management will participate in the following investor conferences in June 2023.